Todd Campbell
Long/short equity, growth, medium-term horizon, registered investment advisor

Covance: Innovation In Drug Development Offers Growth

In 2012, national drug spending sank 1%, according to the IMS Institute for Healthcare Informatics. That marked the first ever decline in drug spending on record.

The drop isn't because we're suddenly healthier. Instead, it's because more than $35 billion of branded drugs lost patent protection.

The threat of generic competition has meant big changes in the way drugs are developed. Instead of expensive in-house research departments, drug makers are shifting to lower cost Contract Research Organizations ("CRO's") such as Covance Inc. (NYSE:CVD).

Covance's drug services menu

Covance's products and services help drug makers identify new treatments, decide whether to pursue them and manage those treatments through required regulatory trials.

The suite of products and services include:

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details